GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microlin Bio Inc (GREY:MICB) » Definitions » EBITDA Margin %

Microlin Bio (Microlin Bio) EBITDA Margin % : 0.00% (As of Sep. 2015)


View and export this data going back to 2014. Start your Free Trial

What is Microlin Bio EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Microlin Bio's EBITDA for the three months ended in Sep. 2015 was $-0.01 Mil. Microlin Bio's Revenue for the three months ended in Sep. 2015 was $0.00 Mil. Therefore, Microlin Bio's EBITDA margin for the quarter that ended in Sep. 2015 was 0.00%.


Microlin Bio EBITDA Margin % Historical Data

The historical data trend for Microlin Bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microlin Bio EBITDA Margin % Chart

Microlin Bio Annual Data
Trend Dec12 Dec13 Dec14
EBITDA Margin %
- - -1,050.00

Microlin Bio Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -875.00 150.00 - -

Competitive Comparison of Microlin Bio's EBITDA Margin %

For the Biotechnology subindustry, Microlin Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microlin Bio's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microlin Bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Microlin Bio's EBITDA Margin % falls into.



Microlin Bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Microlin Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2014 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2014 )/Revenue (A: Dec. 2014 )
=-0.084/0.008
=-1,050.00 %

Microlin Bio's EBITDA Margin % for the quarter that ended in Sep. 2015 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2015 )/Revenue (Q: Sep. 2015 )
=-0.009/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microlin Bio  (GREY:MICB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Microlin Bio EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Microlin Bio's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Microlin Bio (Microlin Bio) Business Description

Traded in Other Exchanges
N/A
Address
MicroLin Bio Inc is engaged in the healthcare sector. It is a therapeutic and diagnostic company focusing on microRNA and its role in oncology. MicroRNAs represent a class of diagnostics and therapeutics that are more effective in the diagnosis and treatment of cancer, with the potential for mitigating side effects in comparison with conventional small molecule drugs or biologics. The company's properties include molecular diagnostics and companion tests, cancer therapeutics, and delivery platform technology. Molecular diagnostics & companion tests include tests such as Lumira, Omira, Colomira, and Promira. Cancer therapeutics includes lumiralin, omiralin, colomiralin, and promirali.

Microlin Bio (Microlin Bio) Headlines

No Headlines